Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma

• Published in: PloS one Vol. 15; no. 5; p. e0233212
• Main Authors: Lin, Wei-Chen, Lin, Yang-Sheng, Chang, Chen-Wang, Chang, Ching-Wei, Wang, Tsang-En, Wang, Horng-Yuan, Chen, Ming-Jen
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 22.05.2020; Public Library of Science (PLoS)
• Subjects: Antiviral agents; Antiviral drugs; Biology and life sciences; Cancer; Cancer staging; Carcinoma; Community colleges; Dasabuvir; Drug therapy; Gastroenterology; Health care facilities; Hepatitis; Hepatitis C; Hepatitis C virus; Hepatocellular carcinoma; Hospitals; Infections; Interferon; Internal medicine; Laboratories; Liver; Liver cancer; Liver cirrhosis; Liver diseases; Magnetic resonance imaging; Medical centers; Medical prognosis; Medical research; Medical schools; Medicine; Medicine and Health Sciences; Nursing; Patient outcomes; Patients; Research and Analysis Methods; Retirement benefits; Sorafenib; Statistical analysis; Survival; Therapy; Time; Tumors; Ultrasonic imaging; Variables; Viruses; Taiwan
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0233212

With the introduction of direct-acting antiviral (DAA) agents, hepatitis C virus (HCV) treatment has dramatically improved. However, there are insufficient data on the benefits of DAA therapy in hepatocellular carcinoma (HCC). The purpose of this study was to investigate the outcome of patients who received DAA therapy after HCC treatment. We retrospectively reviewed patients with HCV-related HCC in a single medical center, and the outcome of patients with or without DAA therapy was analyzed. In total, 107 HCC patients were enrolled, of whom 60 had received DAA therapy after treatment for HCC. There were no significant intergroup differences in age, sex, laboratory results, or tumor burden. A more advanced stage was noted in the no DAA group (P = 0.003). In the treatment modality, sorafenib was commonly prescribed in the no DAA group (P = 0.007). The DAA group had a longer overall survival (OS) time than the no DAA group (P<0.001). When stratified by Barcelona Clinic Liver Cancer staging, the DAA group had better OS in the HCC stages 0-A and B-C (P = 0.034 and P = 0.006). There were 35 patients who received DAA therapy after curative HCC therapy. At a median follow-up of 20 months, 37.1% patients had HCC recurrence after DAA therapy. There was no statistical difference in recurrence-free survival between patients receiving and those not receiving DAA (P = 0.278). DAA therapy improved the survival outcome of HCC patients and did not increase recurrent HCC after curative therapy. .